APA (7th ed.) Citation

Hauge, E., Kristensen, S., Christensen, R., Dreyer, L., Suarez-Almazor, M. E., Uhrenholt, L., & Schlemmer, A. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Hauge, Ellen-Margrethe, Salome Kristensen, Robin Christensen, Lene Dreyer, Maria E. Suarez-Almazor, Line Uhrenholt, and Annette Schlemmer. Dosage Reduction and Discontinuation of Biological Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Protocol for a Pragmatic, Randomised Controlled Trial (the BIOlogical Dose OPTimisation (BIODOPT) Trial). BMJ Publishing Group.

MLA (9th ed.) Citation

Hauge, Ellen-Margrethe, et al. Dosage Reduction and Discontinuation of Biological Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Protocol for a Pragmatic, Randomised Controlled Trial (the BIOlogical Dose OPTimisation (BIODOPT) Trial). BMJ Publishing Group.